Hospira! A Look At Our Bullish Case From 2013 – ValueWalk Premium
Hospira

Hospira! A Look At Our Bullish Case From 2013

Via BlueRidge Capital

In May 2013 we published our research on Hospira (HSP) concluding with some suggestive commentary around the value the company might represent to a potential suitor:

Conventional wisdom in the investment banking world would suggest that once a high quality operating segment is spun-off from a larger conglomerate, it is only logical that it be reacquired years down the road. Academic research suggests that conventional wisdom may be on to something as spin-offs are five times more likely . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click Chat.


X
Saved Articles
Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds.   

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.

SIGN UP NOW
0